Open Access

Selective inhibition of HDAC6 sensitizes cutaneous T‑cell lymphoma to PI3K inhibitors

  • Authors:
    • Malgorzata Bobrowicz
    • Aleksander Slusarczyk
    • Joanna Domagala
    • Michal Dwojak
    • Desislava Ignatova
    • Yun‑Tsan Chang
    • Christoph Iselin
    • Nina Miazek‑Zapala
    • Katsiaryna Marhelava
    • Emmanuella Guenova
    • Magdalena Winiarska
  • View Affiliations

  • Published online on: May 6, 2020     https://doi.org/10.3892/ol.2020.11587
  • Pages: 533-540
  • Copyright: © Bobrowicz et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Histone deacetylase (HDAC) inhibitors, approved for the treatment of cutaneous T-cell lymphoma (CTCL), are non‑selective agents associated with an unsatisfactory response and considerable side‑effects. Targeting single HDAC isoforms is considered to provide novel therapeutic options. HDAC6 is overexpressed in primary samples from patients with CTCL and preclinical studies using transgenic mice that spontaneously develop a CTCL‑like disease, have suggested that combinations including HDAC6 inhibitors may be successful in the treatment of CTCL. PI3K inhibition is currently being tested in clinical trials for CTCL with promising results. Since HDAC6 is known to diminish the activity of Akt via its deacetylation, the aim of the present study was to evaluate the therapeutic potential of selective HDAC6 inhibitors in combination with PI3K inhibitors in CTCL. Through the genetic and pharmacological inhibition of HDAC6, it was demonstrated that combining HDAC6 with PI3K inhibition may be an attractive therapeutic option for patients with CTCL.

Related Articles

Journal Cover

July 2020
Volume 20 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Bobrowicz, M., Slusarczyk, A., Domagala, J., Dwojak, M., Ignatova, D., Chang, Y. ... Winiarska, M. (2020). Selective inhibition of HDAC6 sensitizes cutaneous T‑cell lymphoma to PI3K inhibitors. Oncology Letters, 20, 533-540. https://doi.org/10.3892/ol.2020.11587
MLA
Bobrowicz, M., Slusarczyk, A., Domagala, J., Dwojak, M., Ignatova, D., Chang, Y., Iselin, C., Miazek‑Zapala, N., Marhelava, K., Guenova, E., Winiarska, M."Selective inhibition of HDAC6 sensitizes cutaneous T‑cell lymphoma to PI3K inhibitors". Oncology Letters 20.1 (2020): 533-540.
Chicago
Bobrowicz, M., Slusarczyk, A., Domagala, J., Dwojak, M., Ignatova, D., Chang, Y., Iselin, C., Miazek‑Zapala, N., Marhelava, K., Guenova, E., Winiarska, M."Selective inhibition of HDAC6 sensitizes cutaneous T‑cell lymphoma to PI3K inhibitors". Oncology Letters 20, no. 1 (2020): 533-540. https://doi.org/10.3892/ol.2020.11587